TG Therapeutics, Inc. (TGTX) Stock forecasts
Argus has lowered its target price for TG Therapeutics, Inc. (TGTX) to $58.00, according to a report published on September 16, 2026. The biopharmaceutical company, which focuses on treatments for B-cell diseases, is currently trading at $55.78. The report provides an earnings estimate and a summary of the company's profile.
After tax other income/expense of TG Therapeutics, Inc. – HAN:NKB2
This page from TradingView provides financial information for TG Therapeutics, Inc. (NKB2) listed on the Hannover Stock Exchange. Specifically, it focuses on the "After tax other income/expense" metric for the company. The page also offers navigation to other financial data, news, and community features related to NKB2.
TG Therapeutics, Inc. Revenue Breakdown – HAN:NKB2
TG Therapeutics, Inc. generated €524.72 million last year, primarily from its Novel Treatments for B-cell Diseases segment. This revenue marks an increase from the previous year's €317.81 million, with the United States being the sole geographical contributor to these figures.
Investigation launched into TG Therapeutics' of...
Kuehn Law, PLLC has launched an investigation into TG Therapeutics, Inc. officers and directors for potential self-dealing and breach of fiduciary duties that may harm shareholders. The legal probe could result in damages for shareholders and corporate governance reforms, and long-term shareholders are encouraged to contact the law firm. As of September 28, 2026, TG Therapeutics (TGTX) was trading at USD 57.30 with a market capitalization of $8.79 billion.
TG Therapeutics, Inc. (TGTX) Options Chain - Yahoo Finance
This Yahoo Finance page displays the options chain for TG Therapeutics, Inc. (TGTX). As of the article's data, there are no calls or puts currently listed for the specified contract date, indicating no available options. The page also provides the stock's current price and after-hours trading information.
TG Therapeutics Inc (TGTX) Stock Price Today: $56.12
TG Therapeutics (TGTX) stock is currently trading at $56.3, showing a slight decrease but with bullish technical signals and a positive outlook. The company reported strong revenue growth in Q2 2026, driven by its cornerstone product BRIUMVI, and analysts project significant upside potential despite some recent earnings misses and competitive pressures. Institutional buying interest further supports investor confidence in TGTX.
TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference | TGTX Stock News
TG Therapeutics (NASDAQ: TGTX) announced that its Chairman and CEO, Michael S. Weiss, will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. A fireside chat with Weiss is scheduled for September 14 at 12:00 PM ET, with a live webcast available on the company's website. TG Therapeutics is a biotechnology company focused on treatments for B-cell diseases, known for its FDA-approved drug BRIUMVI® for relapsing forms of multiple sclerosis.
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TG Therapeutics, Inc. announced that its Chairman and CEO, Michael S. Weiss, will participate in the H.C. Wainwright 28th Annual Global Investment Conference. He is scheduled to hold a fireside chat on Monday, September 14, 2026, at 12:00 PM ET. A live webcast of the event will be available on the company's investor relations website.
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TG Therapeutics announced that its Chairman and CEO, Michael S. Weiss, will participate in the H.C. Wainwright 28th Annual Global Investment Conference with a fireside chat scheduled for September 14, 2026, at 12:00pm ET. A live webcast will be available on the company's investor relations website. TG Therapeutics is a commercial-stage biotechnology company focused on B-cell diseases, with an FDA-approved treatment, BRIUMVI®, for relapsing forms of multiple sclerosis.
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) is anticipated to report a significant year-over-year increase in earnings and higher revenues for the quarter ended June 2026. The company is expected to post earnings of $0.41 per share, a 141.2% increase, on revenues of $230.77 million, up 63.5%. With a positive Earnings ESP of +7.98% and a Zacks Rank #3, TG Therapeutics is likely to beat the consensus EPS estimate.
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
TG Therapeutics, Inc. announced that its Chairman and CEO, Michael S. Weiss, will participate in the Cantor Global Healthcare Conference. He is scheduled to hold a fireside chat on September 9, 2026, at 11:30 AM ET. A live webcast of the event will be available on the company's investor relations website.
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that its Chairman and CEO, Michael S. Weiss, will participate in a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026, at 11:30 AM ET. A live webcast of the event will be available on the company's investor relations website. TG Therapeutics is a biotechnology company focused on treatments for B-cell diseases, with an FDA-approved drug, BRIUMVI®, for relapsing forms of multiple sclerosis.
TG Therapeutics (TGTX) Tests A Key Moving Average, Is The Stock Fully Priced?
TG Therapeutics (TGTX) stock has formed a cup-style base after an early August sell-off and is now testing a key moving average. While the company has shown strong recent returns, analysts have a consensus price target of $51.71, suggesting the stock is currently slightly overvalued at its last close of $56.01, or fairly priced at its current price of $53.22. However, when viewed through a P/E lens, the stock's 18x earnings is slightly above the US Biotechs average but below an estimated fair ratio of 25.7x, indicating mixed signals for investors.
TG Therapeutics (TGTX) Stock Still Looks Cheap Even After Strong Returns
TG Therapeutics (TGTX) has seen significant returns over the past three years, yet its stock appears undervalued based on current valuation checks. The company trades at a lower P/E ratio compared to its industry and peers, and its tailored fair P/E also suggests it's priced under its benchmark. The key to future valuation lies in its ability to convert its pipeline into sustainable earnings, with differing community views on its flagship product BRIUMVI.
TGTX Jumps As TG Therapeutics Hikes 2026 Revenue Outlook
TG Therapeutics Inc. (TGTX) shares jumped 9.62% after the company increased its 2026 revenue guidance to approximately $950 million, driven by strong U.S. BRIUMVI sales for multiple sclerosis treatment. While Q2 2026 EPS missed estimates, revenue growth was robust at 70% year-over-year, and analysts have raised price targets, reflecting bullish sentiment despite some event-driven volatility and takeover rumors. The company's strong commercialization of BRIUMVI, high gross margins, and positive pipeline data underpin its growth trajectory.
TG Therapeutics (TGTX) Stock Still Looks Cheap Even After Strong Returns
TG Therapeutics (TGTX) has shown impressive returns of 388.0% over three years, yet its stock appears undervalued based on various valuation checks. The company's P/E ratio of 16.2x is below both the biotech industry average and its peer group, suggesting it's priced lower than its implied fair value. While there's a strong bull case around its drug BRIUMVI, risks include reliance on this single revenue source and potential competitive threats.
TGTX Stock Whipsaws As BRIUMVI Growth Fuels Bold 2026 Outlook
TG Therapeutics (TGTX) stock saw an 11.61% increase after upbeat trial results and raised 2026 revenue guidance to approximately $950 million, primarily driven by strong BRIUMVI sales. Despite a mixed Q2 2026 earnings report with an EPS miss, the company's strong top-line growth, $612 million in cash, and pipeline expansion into new indications like myasthenia gravis and schizophrenia are fueling investor confidence. Wall Street analysts have also increased price targets for TGTX, reflecting a belief in its long-term growth story.
Price to book forward of TG Therapeutics, Inc. – BX:NKB2
This article provides a brief financial data point for TG Therapeutics, Inc. (BX:NKB2) focusing on its forward price-to-book ratio. The content indicates a period value, change, and percentage change for this metric, suggesting it is a snapshot of recent financial performance. The article appears to be a data-centric entry from a financial platform like TradingView.
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
Shares of TG Therapeutics (TGTX) have increased by 29% in the past three months, driven primarily by strong sales of its drug, Briumvi. The company has raised its 2026 total revenue guidance to approximately $925 million, reflecting Briumvi's robust demand. TG Therapeutics is also advancing Briumvi through additional late-stage studies for other autoimmune diseases, with potential for further revenue diversification and stock catalysts.
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices is now solely focused on handheld chemical and drug detection technologies for public safety and defense markets, a strategic shift after divesting its life-sciences business. The company's products, including the MX908, VipIR, and NIRLab, are designed for rapid identification of substances like synthetic opioids and industrial chemicals, helping address laboratory backlogs and ensuring quick responses in hazardous situations. With a substantial market opportunity, 908 Devices is also engaging in government funding programs and military partnerships, and plans to release a smaller, next-generation MX908 device.
How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story
TG Therapeutics reported a significant revenue increase in Q2 2026 to US$240.34 million, though net income decreased. The company raised its full-year 2026 revenue guidance to approximately US$950 million, signaling management confidence in its key drug BRIUMVI. This update reinforces the revenue growth aspect of its investment story, but highlights ongoing concerns about profitability fluctuations, pricing pressure, and the risks associated with a single-product focus.
TG Therapeutics (TGTX) Raised Revenue Guidance After Q2, Is It Still Below Fair Value?
TG Therapeutics (TGTX) recently reported its Q2 2026 results, showing higher revenue, lower net income, and raised full-year revenue guidance to about US$950 million. Despite a recent 13% drop, the stock is up 64% year-to-date and is considered modestly undervalued at $47.94 against a narrative fair value of $51.71, largely driven by the anticipated performance of its drug BRIUMVI. The company's future growth hinges on the successful launch of subcutaneous BRIUMVI and expanded market access, though competitive pressures pose a risk to its valuation.
Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX
Assenagon Asset Management S.A. significantly reduced its stake in TG Therapeutics (NASDAQ:TGTX) by 82% in Q2 2026, selling over 400,000 shares but still retaining a position worth approximately $5 million. Despite mixed analyst ratings, institutional investors hold a substantial portion of the company. TG Therapeutics reported strong revenue growth but missed EPS estimates, with its stock currently trading at $49.50.
Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX
Bank of America Corp DE significantly increased its stake in TG Therapeutics (NASDAQ:TGTX) by 71.7% in the first quarter, acquiring an additional 610,195 shares. This purchase brings their total holdings to 1.46 million shares, valued at approximately $48.5 million. Other institutional investors also increased their positions, with overall institutional ownership reaching 58.58%. Despite strong revenue growth, TG Therapeutics missed EPS estimates in its latest earnings report, and analysts currently hold an average "Hold" rating with a target price of $63.
US High Growth Tech Stocks To Watch: 3 Top Picks
The US market has performed flat recently but is up 19% over the past year, with earnings projected to grow 17% annually. This article identifies high-growth tech stocks by focusing on companies with strong innovation and financial health, presenting three top picks: TG Therapeutics (TGTX), Precigen (PGEN), and Zymeworks (ZYME). Each company is analyzed for its operational focus, recent financial performance, and growth potential within the biotechnology sector.
TGTX Stock Slips After Earnings – But CEO's $1B Briumvi Outlook Keeps Retail Bullish
Despite a significant Q2 earnings per share miss, TG Therapeutics (TGTX) saw its stock slip by 5%, but retail investors remain bullish due to CEO Michael Weiss's optimistic outlook for its MS drug, Briumvi. The company raised its 2026 total global revenue target to $950 million and U.S. Briumvi net product revenue guidance to $890 million-$905 million, projecting an annualized U.S. revenue run rate of $1 billion by year-end. TG Therapeutics also has upcoming clinical trial results for Briumvi and its Azer-Cel therapy.
TG Therapeutics, Inc. $TGTX Position Trimmed by First Trust Advisors LP
First Trust Advisors LP significantly reduced its stake in TG Therapeutics (NASDAQ:TGTX) by 43.6% in the first quarter, selling 38,545 shares and retaining 49,947 shares valued at $1.66 million. Despite institutional ownership of 58.58%, the biopharmaceutical company reported mixed financial results, with revenue exceeding estimates but earnings per share missing consensus. Analyst sentiment for TG Therapeutics is divided, with an average "Hold" rating and a price target of $63.00 against a recent price of $49.76.
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript
TG Therapeutics reported strong Q2 2026 financial results, with U.S. BRIUMVI revenue reaching $227.7 million, a 64% increase year-over-year. The company raised its full-year U.S. revenue guidance to $890-$905 million, driven by record patient starts and expanded physician adoption. TG Therapeutics is also making significant progress in developing a subcutaneous formulation of BRIUMVI and expanding its pipeline into new autoimmune indications, aiming for a broader development-stage organization.
TG Therapeutics, Inc. (TGTX) Stock forecasts
Argus has raised its target price for TG Therapeutics, Inc. (TGTX) to $60.00, noting the company's focus on novel treatments for B-cell diseases. The biopharmaceutical company is described as fully integrated and commercial-stage. The current stock price for TGTX is $49.76.
TG Therapeutics (TGTX) Is Down 7.4% After Q2 Profit Drop Despite Higher 2026 Revenue Guidance – Has The Bull Case Changed?
TG Therapeutics (TGTX) reported a Q2 2026 profit drop despite increased revenue and raised full-year 2026 revenue guidance to approximately US$950 million, driven by confidence in its B-cell disease franchise and anticipated launch of subcutaneous BRIUMVI. While the company projects significant revenue and earnings growth by 2029, investors are advised to consider the risks associated with reliance on a single IV franchise and potential payer pressure on drug pricing.
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Brokerages
TG Therapeutics (NASDAQ:TGTX) has received a consensus "Hold" rating from nine brokerages, with an average 12-month price target of $63.00. The company recently reported a 70.2% year-over-year revenue increase to $240.34 million, surpassing estimates, though adjusted EPS of $0.05 missed the $0.31 consensus. Institutional investors hold 58.58% of the stock, with major firms like BlackRock, Vanguard, and State Street increasing their positions.
Director gifts 6,050 TG Therapeutics (TGTX) shares to 501(c)(3)
TG Therapeutics director Laurence N. Charney gifted a total of 6,050 shares of common stock to a 501(c)(3) institution on August 6-7, 2026. The shares were transferred at $0.00 per share, and Charney retains no beneficial ownership or pecuniary interest in the gifted stock. His remaining holdings include restricted common stock that vests over time.
TG Therapeutics (TGTX) Is Down 7.4% After Q2 Profit Drop Despite Higher 2026 Revenue Guidance – Has The Bull Case Changed?
TG Therapeutics reported a 7.4% stock drop following a Q2 2026 profit decline, despite increasing its full-year 2026 global revenue guidance to US$950 million. The company's investment narrative relies heavily on the continued success of BRIUMVI and its upcoming subcutaneous version, which is expected to be a major catalyst. While revenue growth is strong, potential risks include reliance on a single IV franchise and payer pressure on drug costs.
ETFs Investing in TG Therapeutics, Inc. Stocks
This article lists various ETFs that invest in TG Therapeutics, Inc. stocks, providing detailed information such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return for each fund. The ETFs primarily focus on small-cap, total market, or health care sectors, offering investors diverse options to gain exposure to TG Therapeutics, Inc. through lower-risk investment vehicles.
TG Therapeutics 2026: Revenue $240.34M, EPS $0.05— 10-Q Summary
TG Therapeutics reported its 2026 quarterly results with revenue of $240.34 million, an increase from $141.15 million in the prior year, and diluted EPS of $0.05, down from $0.17. The net income for the quarter was $7.78 million, compared to $28.19 million in the year-ago period. Revenue growth was primarily driven by increased U.S. penetration and ex-U.S. sales through a partner, along with continued adoption of BRIUMVI following FDA approval and positive clinical trial results for its pipeline.
TG Therapeutics (NASDAQ: TGTX) grows 2026 revenue to $445 million
TG Therapeutics (NASDAQ: TGTX) reported strong financial results for the first half of 2026, with total revenue reaching $445.3 million, primarily driven by BRIUMVI sales for multiple sclerosis both in the U.S. and internationally. The company achieved profitability, posting a net income of $27.6 million for the period, and anticipates existing liquidity and projected revenues will fund operations for over twelve months without needing to raise additional capital. TG Therapeutics also highlighted progress in its clinical pipeline, including positive Phase 3 topline data for a simplified BRIUMVI dosing regimen and Phase 1 data for subcutaneous ublituximab, alongside initiating new trials for BRIUMVI in myasthenia gravis and schizophrenia.
TG Therapeutics stock price target raised to $78 by H.C. Wainwright
H.C. Wainwright has increased its price target for TG Therapeutics (NASDAQ:TGTX) to $78 from $77, maintaining a Buy rating after the company's strong second-quarter 2026 earnings report. The firm noted Briumvi's US revenue exceeded estimates and its market share grew, leading TG Therapeutics to raise its 2026 total global revenue guidance. Despite a slight dip in share price post-earnings, the stock has shown significant year-over-year returns, and an InvestingPro analysis suggests it is undervalued.
TG Therapeutics (TGTX) Stock May Be Undervalued As Revenue Guidance Rises
TG Therapeutics (TGTX) stock is currently viewed as undervalued, despite a significant 3-year return. The company's P/E ratio is lower than both the biotech industry average and its peers, suggesting a discount relative to its fundamentals. While strong revenue growth from BRIUMVI is positive, earnings have fallen short of some expectations, prompting questions about the market's caution regarding its long-term profitability.
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
TG Therapeutics announced strong second-quarter 2026 financial results, with total global revenue reaching approximately $240 million and U.S. BRIUMVI® net product revenue at $228 million. The company has raised its full-year 2026 revenue guidance for both total global revenue to $950 million and U.S. BRIUMVI® net product revenue to between $890 million and $905 million. This positive outlook is driven by excellent commercial performance and progress in BRIUMVI®'s subcutaneous program, a simplified initiation regimen, and expansion into myasthenia gravis and schizophrenia indications.
TG Therapeutics (TGTX) Is Down 15.9% After Q2 Miss But Raised 2026 Outlook - What's Changed
TG Therapeutics (TGTX) reported a Q2 2026 revenue increase but missed EPS estimates, leading to a 15.9% stock drop. Despite this, the company raised its 2026 global revenue outlook to about US$950 million, driven by confidence in Briumvi's momentum and its broader pipeline. Investors are now evaluating how the raised guidance and Briumvi's growth will impact the company's future performance and current investment narrative, with a focus on Briumvi's expansion into the self-administered MS market.
TG Therapeutics (TGTX) Stock Sinks As Profit Shrinks Behind BRIUMVI Growth
TG Therapeutics (TGTX) stock dropped 11% after earnings, despite strong revenue growth from its multiple sclerosis drug, BRIUMVI. The company's profit shrank significantly due to heavy manufacturing-related charges, raising concerns about margin pressure and reliance on BRIUMVI. This performance has fueled arguments from bears about scaling costs and manufacturing complexity impacting overall profitability.
TG Therapeutics (NASDAQ:TGTX) Falls as Q2 Revenue Beats but EPS Misses, Guidance Raised Below Estimates
TG Therapeutics (TGTX) reported mixed Q2 2026 financial results, with total global revenue exceeding consensus estimates but non-GAAP earnings per share significantly missing expectations. The company also raised its full-year guidance, though it still fell slightly below analyst projections, leading to a negative reaction from investors. The revenue beat was primarily attributed to the commercial performance of BRIUMVI.
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) reported Q2 earnings of $0.05 per share, significantly missing the Zacks Consensus Estimate of $0.41 per share, representing an 87.81% negative surprise. Despite the earnings miss, the biopharmaceutical company's revenues of $240.34 million surpassed estimates by 4.08% and marked a substantial increase from the previous year. The stock has outperformed the S&P 500 this year, but its future performance will depend on management's commentary and ongoing earnings estimate revisions, currently indicating a Zacks Rank #3 (Hold).
TG Therapeutics Releases Q2 2026 Financial Results
TG Therapeutics (TGTX) reported its Q2 2026 financial results, showing significant revenue growth driven by BRIUMVI U.S. net product revenue. Despite a 70.3% increase in revenue to $240.3M, the company missed analyst profit expectations, reporting diluted earnings of $0.05 per share against an estimated $0.33. The divergence between revenue and earnings suggests increased investment, while the company maintains a full-year revenue guidance of $950M.
TG Therapeutics reports Q2 2026 revenue ~$240M, raises 2026 BRIUMVI U.S. revenue guidance
TG Therapeutics reported strong Q2 2026 financial results, with total global revenue reaching $240.3 million and U.S. BRIUMVI net product revenue at $227.7 million, marking a 64% year-over-year increase in U.S. sales. The company has raised its full-year 2026 total global revenue target to approximately $950 million and its BRIUMVI U.S. net product revenue target to $890–905 million. Additionally, TG Therapeutics provided updates on its BRIUMVI commercial performance, subcutaneous development, and pipeline expansion into new indications.
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
TG Therapeutics reported strong second quarter 2026 financial results, with total global revenue of approximately $240 million, including $228 million in U.S. BRIUMVI net product revenue. The company raised its full-year 2026 total global revenue target to $950 million and U.S. BRIUMVI net product revenue target to $890-$905 million. Key developments include positive Phase 3 ENHANCE data for a simplified BRIUMVI initiation regimen, progress in subcutaneous BRIUMVI, and expansion into myasthenia gravis and schizophrenia.
TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss
TG Therapeutics has raised its full-year 2026 revenue guidance, projecting that its multiple sclerosis drug, Briumvi, is on track to achieve an annualized U.S. revenue run rate of approximately $1 billion. This update follows a strong Q2 performance where global revenue increased by 70%, surpassing Wall Street estimates, despite a significant drop in earnings per share. Retail investor sentiment on platforms like Stocktwits remains bullish, largely disregarding the EPS miss and anticipating future stock growth.
How Tg Therapeutics Inc. (TGTX) Affects Rotational Strategy Timing
This article analyzes Tg Therapeutics Inc. (TGTX) and its impact on rotational strategy timing, highlighting weak near and mid-term sentiment but a positive long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels for various time horizons.
TG Therapeutics, Inc. Revenue Breakdown – NASDAQ:TGTX
TG Therapeutics, Inc. (NASDAQ: TGTX) generated $616.29 million USD in revenue last year. The primary source of this revenue, $616.29 million USD, came from its "Novel Treatments for B-cell Diseases" segment, an increase from $329.00 million USD the previous year. All reported revenue originated from the United States.
TG Therapeutics earnings on deck: Can BRIUMVI sustain momentum?
TG Therapeutics is preparing to report second-quarter earnings, with investors closely watching to see if its multiple sclerosis drug, BRIUMVI, can maintain its sales momentum. Analysts are expecting significant sequential improvements in both earnings per share and revenue, but also scrutinizing the company's profitability following a Q1 earnings miss. The report will also shed light on pipeline expansion, including a Phase 2 trial for BRIUMVI in schizophrenia and updates on a simplified dosing schedule.
